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Despite stringent procedures to secure the best HLA matching between donors and recipients, life-
threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Study-
ing single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify
patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory
molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association
with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched
cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better
disease-free survival (P ¼ .029) and overall survival (P ¼ .009) with less treatment-related mortality (P ¼ .006).
Our data demonstrate the TNFSF4C variant had a higher afﬁnity for the nuclear transcription factor Myb and
increased percentage of TNFSF4-positive B cells after stimulation compared with CT or TT genotypes. How-
ever, these associations were not validated in a more recent cohort, potentially because of changes in stan-
dard of practice or absence of a true association. Given the discovery cohort, functional data, and importance
of TNFSF4 in infection clearance, TNFSF4C may associate with outcomes and warrants future studies.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although hematopoietic stem cell transplantation
(HSCT) has become the gold standard therapy for hemato-
logic disorders and malignancies, the full therapeutic
potential of HSCT has been limited because of its compli-
cations. Although the standardization of pretransplant
donorerecipient matching for HLAs has greatly improved
post-HSCT outcomes, the mortality rate still remains twice
that of the general population even in patients whodgments on page 35.
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ty for Blood and Marrow Transplantation.survived 2 or more years after allogenic HSCT [1]. This
excess mortality is caused by a number of complications
post-transplantation such as graft-versus-host disease
(GVHD), infection, and relapse of the primary disease [1,2].
There is growing evidence to support the importance
of genetic variability outside the HLA system that is
contributing to the heterogeneity in HSCT outcomes [3-5].
Responses to alloantigen, tumor surveillance, and infectious
complications post-HSCT rely heavily on a functional im-
mune system. Costimulatory molecules represent an essen-
tial regulatory component of the immune system, which
may be functionally affected by gene polymorphisms [5,6].
For T cell activation 2 activation signals are required. The ﬁrst
signal occurs after the T cell receptor and a coreceptor
interact with the antigen peptide presented on an MHC
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costimulatory signal occurs when 1 or more T cell surface
receptors engage with their speciﬁc ligands on antigen-
presenting cells [7-10]. Conversely, negative costimulatory
molecules decrease T cell proliferation and cytokine pro-
duction, promote T cell anergy or apoptosis, and induce the
activity of regulatory T cells [11].
For this study we selected single nucleotide poly-
morphisms (SNPs) based on a stepwise criteria from cos-
timulatory genes, which have an established association in
human and animal HSCT outcomes [12-14]. SNPs needed to
have a strong linkage disequilibrium to additional tagged
SNPs within their gene to maximize a subset of informative
SNPs. Each SNP required an adequate minor allelic frequency
of polymorphism above 5% to ensure the least common
variant was present in our population. Finally, every SNP
required enough subjects in our population to detect a sig-
niﬁcant association at 80% power. From these guidelines we
created a panel of SNPs with a high likelihood of discovering
an association in our HSCT population. Determining novel
predictors could help develop a pretransplant matching
system to identify patients at risk and modify immunosup-
pressive regimens based on their risk assessment.
The tumor necrosis factor ligand superfamily member 4
(TNFSF4) and tumor necrosis factor receptor superfamily
member 4 (TNFRSF4) pathway represent key positive cos-
timulatory signals required for cell activation. TNFRSF4 is
present on both activated CD4þ and CD8þ T cells and its
cognate ligand, TNFSF4, is expressed on dendritic cells, B
cells, and activated endothelial cells [15]. Signaling through
the TNFSF4/TNFRSF4 pathway facilitates Th 2 differentiation,
enhances effector CD8þ T cell memory commitment and
promotes cytokine production [16,17]. Gene polymorphisms
in TNFSF4 have been associated with atherosclerosis and
systemic lupus erythematosus [18-20]. These studies postu-
late that TNFSF4 is a major component in the T celleantigen-
presenting cell interaction, leading to activation of immune
cells to produce proinﬂammatory cytokines and chemokines,
resulting in active disease. The role of TNFSF4 in determining
the post-HSCT outcomes remains to be explored.
Infectious complications are a contributing source of
severe morbidity and nonrelapse-related mortality in unre-
lated donor allogeneic HSCT [21]. They account for a higher
percentage of mortality compared with GVHD in both
HLA-identical sibling and unrelated donor transplants stud-
ied over a 5-year period [22]. Although the early prophylactic
regimens reduce the incidence of early infection, the risk
of late infection remains [23]. Deﬁciencies in the function
of immunoregulatory genes that activate the cellular and
humoral immune responses can be the underlying cause of
an increased risk of infection. As part of the immune system’s
response to infection, activation of T cells through TNFSF4
costimulation has been shown to effectively clear pathogens
[15,24]. Genetic variation may inﬂuence the timing and
strength of TNFSF4 signaling to effectively respond to in-
fectious pathogens.
In this study we carefully chose candidate SNPs found
within a group of extensively studied costimulatory
molecules that might associate with HSCT outcomes.
We analyzed genetic data from discovery (n ¼ 1157) and
validation (n ¼ 1188) cohorts using HLA-matched (at the
HLA-A, -B, -C, -DRB1, and -DQB1 loci) HSCT recipients and
their respective donors and then searched for associations
with important transplant outcomes.METHODS
Patient Population
A discovery cohort of 1157 and a validation cohort of 1188 recipi-
entedonor pairs from unrelated HLA-A, -B, -C, -DRB1, and -DQB1 allele-
matched transplantations facilitated by the National Marrow Donor
Program (NMDP) were included in the study. A detailed description can be
found in Supplementary Methods. Patient data were acquired from the
Center for International Blood and Marrow Transplant Research, a research
afﬁliation between the Medical College of Wisconsin, and the NMDP.
Observational studies conducted by the Center for International Blood and
Marrow Transplant Research were performed in compliance with the
Privacy Rule under the Health Insurance Portability and Accountability Act
of 1966, as a Public Health Authority, and in compliance with all applicable
federal regulations pertaining to the protection of human research partici-
pants and the Declaration of Helsinki as determined by continuous review of
the Institutional Review Board of the NMDP.
Deﬁnition of Outcome
The primary endpoints analyzed in the study were overall survival (OS),
disease-free survival (DFS), treatment-related mortality (TRM), relapse,
acute GVHD (aGVHD) grades II to IV and III to IV occurring within the ﬁrst
100 days post-transplant, and chronic GVHD (cGVHD). Our analysis of OS
treated death from any cause as the event, and surviving patients were
censored at the date of last contact. For analysis of DFS, failures were relapse
or death from any cause with patients who were alive and in complete
remission censored at time of last follow-up. TRM was deﬁned as death
during a continuous complete remission. Relapse was deﬁned as clinical or
hematologic relapse of primary disease with death without evidence of
disease as a competing risk. For chronic myeloid leukemia patients our
deﬁnition of relapse included cytogenetic, molecular, and hematologic
relapse as an event. Assessment of aGVHD grades II to IV and III to IV were
deﬁned using the Glucksberg scale [25], and extensive cGVHD was deﬁned
according to the Seattle criteria [26].
Genotyping
We genotyped 9 SNPs located in 5 immunoregulatory genes: CD274,
CD40, CD154, CD28, and TNFSF4 (Supplementary Table 1). These SNPs were
selected based on strong linkage disequilibrium to tagged SNPs within
their gene and power calculations suggested in our population a high likeli-
hood of discovering an association. For the discovery set, genomic DNA was
isolated from cryopreserved leukocytes from donor and recipient blood
samples provided by the NMDP Research Sample Repository following
the manufacturer’s protocol (Promega, MAdison, WI). Isolated DNA was
quantitated using a Nanodrop (Thermo Scientiﬁc, Waltham, MA) and whole
genome ampliﬁed with Phi29 DNA polymerase. For the validation set,
genomic DNA was isolated from frozen blood samples using the QIAmp 96
DNA Blood Kit and the manufacturer’s protocol (Qiagen, Valencia, CA). Gen-
otyping was then performed using a Taqman SNP genotyping assay (Applied
Biosystems, Foster City, CA) and automated genotype calling software. Sam-
ples in the discovery (n ¼ 213) and validation (n ¼ 12) cohorts where a SNP
genotype was not obtained due to DNA degradation or minimal isolated
genomic DNA were excluded from further analysis.
SNP Selection and Identiﬁcation of Tag SNPs
SNPs were investigated using the Hapmap Genome Browser Phase 1 and
2 full dataset (International Hapmap Project, http://www.hapmap.org/).
Gene SNP data from the white population was imported into Haploview
(http://www.broad.mit.edu/mpg/haploview/) using the Hapmap format
function. The uploaded SNP data were further modeled by setting the
following Haploview parameters: Hardy-Weinberg P cutoff of .001, a mini-
mum genotype percent of 80, a maximum number Mendel error of 1, and a
minimumminor allele frequency of .05. The minor allele frequency cutoff of
5% was selected for compatibility with HapMap, which includes only those
SNPs with allele frequencies greater than .05. The tagger function in Hap-
loview was performed using pair-wise tagging only with an r2 equal to .8.
Identiﬁed tag SNPs and the corresponding predicted common SNPs were
compiled.
Statistical Analysis
Discovery set
Univariate probabilities of DFS and OS were calculated using the Kaplan-
Meier method. The log-rank test was used for comparing survival curves.
Probabilities of TRM, relapse, aGVHD, and cGVHD were calculated using
cumulative incidence estimates. The cumulative incidence calculated for
aGVHD and cGVHD treated death as a competing risk [27]. Relapse was
treated as a competing risk for TRM and vice versa.
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performed using the Cox proportional hazards regression models with a
multivariate analysis performed to identify clinical variables that were
associated with particular outcomes. Clinical variables considered in the
models include disease, disease status, conditioning regimen, cytomegalo-
virus match, Karnofsky score, graft type, GVHD prophylaxis, year of trans-
plant, recipient age, donor age, and sex. For each outcome, all variables
were examined for proportional hazards. Factors violating the proportional
hazards assumption were adjusted by stratiﬁcation. The stepwise model
building approach was then used in developing models for all the outcomes.
OS was adjusted for disease, disease stage, conditioning regimen, patient
age, and GVHD prophylaxis and stratiﬁed by graft type and Karnofsky score.
DFS was adjusted for disease, disease stage, cytomegalovirus match, patient
age, and conditioning regimen and stratiﬁed by disease type and Karnofsky
score. Relapse was adjusted for disease, disease stage, conditioning regimen,
and donor sex. TRM was adjusted for disease stage, conditioning regimen,
and patient age and stratiﬁed by disease, graft type, and Karnofsky score.
aGVHD grades II to IV was adjusted for disease, disease stage, graft type, and
GVHD prophylaxis. aGVHD grades III to IV was adjusted for disease, disease
stage, conditioning regimen, and year of transplant. cGVHDwas adjusted for
disease and patient age and stratiﬁed by GVHD prophylaxis.
Potential interactions between the genetic variants and clinical cova-
riates were tested and were not present. Because of the possibility of Type I
error occurring from multiple comparisons, the genetic associations were
referred to as statistically signiﬁcant when P  .01. SAS software, version 9.2
(SAS Institute, Cary, NC), was used in all the analyses.
Weused apriori power calculations todetermine the powerof our cohort
(1157 donorerecipient pairs) to detect signiﬁcant associations between each
geneSNPandHSCToutcomes. Setting the odds ratio to equal 1.5 for each gene
SNP with minor allelic frequency  5%, assuming a Type 1 error level of .05,
calculations were performed using the Quanto software (http://hydra.us-
c.edu/GxE/). Using our cohort we calculated the minimum number of in-
dividuals required to attain 80% power in our study to identify signiﬁcant
associations between HSCT outcomes and 9 costimulatory gene SNPs.
For additional statistical analyses, the association between TNFSF4 SNP
rs10912564 genotypes and causes of death were performed using a chi-
square test, and TNFSF4 in vitro data were analyzed by Student’s t-test.
Results were considered statistically signiﬁcant when P  .05.
Validation set
To validate the SNP rs10912564 observations in the discovery cohort, we
assembled an independent cohort of 1200 unrelated donorerecipient pairs
using the same covariates from the discovery cohort.
DNA Protein Interaction ELISA
DNA protein interaction ELISA has been described previously [28].
Brieﬂy, we created 50 biotin linked 30-mer double-stranded DNA oligomer
sequences corresponding to the rs10912564 region of TNFSF4 gene with
rs10912564C/T located in the center position in bold (50-TAGCAGTATGT
TAACGGAAGCATGTTCATG-30) and (50-TAGCAGTATGTTAATGGAAGCATGTT
CATG-30) (Integrated DNA Technologies, Coralville, IA). Ninety-sixewell
plates were coated with streptavidin (15520; Pierce Biotechnologies, Rock-
ford, IL) and incubated with 2 pmol DNA oligo probes for 1 hour at 37C,
blocked with 5% milk for 30 minutes, and incubated with 5 mg of Jurkat cell
nuclear extract (36110; Active Motif, Carlsbad, CA). After 1 hour c-myb was
detected by primary c-myb antibody (1:500, D-7, sc-74512) and anti-mouse
horseradish peroxidase linked secondary (1:1500, sc-2031) antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA). After each step thewells werewashed
3 times with PBS Tween-20. An o-phenylenedianime dihydrochloride sub-
strate (P9187; Sigma, St. Louis, MO) produced a peroxidase reaction that was
quantitated by measuring absorbance at 450 nm on an ELISA reader.
Flow Cytometry
Peripheral blood mononuclear cells (available from the NMDP Research
Repository for in vitro studies) from 12 HSCT donors were tested with 4 each
from the CC, CT, and TT rs10912564 genotypes. Cells were plated in a 96-well
plate at .25  106 and were stimulated with 10 mg/mL F(ab’)2 anti-human
IgM Fc5m (Jackson Immunoresearch, West Grove, PA) and 5 mg/mL CD40
(S2C6) (Mabtech, Cincinnati, OH) monoclonal antibody for 72 hours shown
to upregulate TNFSF4 and c-myb in B cells [29,30]. Cells were stained for
30 minutes on ice with CD19-FITC (HIB19), TNFSF4-PE (11C3.1) (Biolegend,
San Diego, CA), and 7AAD (BD Biosciences, San Jose, CA) and run on a
FACScan ﬂow cytometer (BD Biosciences). A PE mouse IgG1 kappa MOPC-21
isotype control (Biolegend) was used to estimate nonspeciﬁc binding of the
TNFSF4-PE antibody. Dead cells were excluded by 7AAD staining, and a
forward and side scatter lymphocyte gate was applied. The percentage of
TNFSFþCD19þ high cells was analyzed using FloJo version 10 (Tree Star,
Ashland, OR) and Prism version 4.0a (GraphPad Software, Inc., La Jolla, CA).RESULTS
Genotyping of Costimulatory Molecule Genetic Variants
Costimulatory molecule SNPs were genotyped using
automated technology in discovery (n¼ 1370) and validation
(n ¼ 1200) cohorts totaling 2570 recipients and their
respective donors. Genotyping was successful for 84.4%
(n¼ 1157) and 99% (n¼ 1188) in our discovery and validation
cohorts, respectively. The allele frequencies observed in our
predominately white transplant population were compara-
blewith those obtained in the Hapmap database phase IIþ III
on NCBI B36 assembly, dbSNP b126 [31]. We found each
genetic variant to be in Hardy-Weinberg equilibrium, con-
ﬁrming no evolutionary selection and validating the accu-
racy of our genotyping (Supplementary Table 1). Focusing on
the rs10912564 TNFSF4 genotypes, the characteristics (age at
transplant, Karnofsky score, sex, disease, stage, etc.) of C/C
recipients shown in Table 1 were not signiﬁcantly different
compared with the general population tested by the
chi-square test.Outcome Analysis by Donor and Recipient Costimulatory
Molecule Genotypes
Initially, we examined the association between cos-
timulatory molecule SNPs and transplant outcomes in our
discovery cohort. We found a signiﬁcant association with
increased OS (hazard ratio, .823; 95% conﬁdence interval,
.718 to .953; P ¼ .0085; Table 2, Figure 1) in donors carrying
the TNFSF4 CC genotype compared with TT or CT. Interest-
ingly, we found a signiﬁcant decrease in TRM (hazard ratio,
.778; 95% conﬁdence interval, .650 to .931; P ¼ .006; Table 2,
Figure 1) in CC rs10912564 genotyped donors. When TRM
was analyzed using T cell depletion status we observed
similar hazard ratios, suggesting T cell depletion status did
not affect TRM (Supplementary Table 2). There was no as-
sociation between rs10912564 with other HSCT outcomes
such as relapse, aGVHD, or cGVHD (Table 2, Figure 1). SNPs in
genes CD274 and CD40 of recipients were associated with
HSCT outcomes, but this requires additional validation
testing (Supplementary Table 3).
To determine if SNP rs10912564 had any effect on
mortality in our patient population, we analyzed causes of
death comparing patients transplanted with rs10912564 CC
or TT/TC genotyped donors (Supplementary Table 4). We
found a signiﬁcant increase in mortality due to infection in
the TT/TC group compared with CC in our discovery cohort
(P ¼ .014). This association was present in patients with no
GVHD and in contrast was absent in the GVHD cohort
(Supplementary Table 5). A cause of death analysis is difﬁ-
cult to deﬁne a speciﬁc variable, and these results require
further investigation into the rate of infection. Although a
larger and well-designed study is needed to further support
these data, TNFSF4 has been shown to be critically required
to maintain T cell responses during persistent viral
infections [32].
To validate the associations observed with TNFSF4
SNP rs10912564, we identiﬁed a much more recent cohort
available to us through the NMDP. We found no association
between SNP rs10912564 and transplant outcomes or cause
of death in this validation cohort (Table 2 and Supplementary
Table 6). Not surprisingly, we noted a number of contributing
factors that were signiﬁcantly different between the cohorts,
including age, disease type, graft type, GVHD prophylaxis,
donor age, and year of transplant (Table 3). These factors
could potentially impact the clinical relevance of SNP
Table 1
Characteristics of Patients Receiving a First Myeloablative Transplant for
AML, ALL, CML, or MDS analyzed by rs10912564 SNP Donor Typing in the
Discovery Cohort*
Characteristic TT þ CT CC P
Total number of patients 606 551
Number of centers 97 96
Median age, yr (range) 38 (<1-64) 36 (1-65) .93
Age at transplant, yr .68
0-9 47 (8) 38 (7)
10-19 62 (10) 59 (11)
20-29 94 (16) 96 (17)
30-39 165 (27) 135 (25)
40-49 161 (27) 140 (25)
50 and older 77 (13) 83 (15)
Male sex 352 (58) 317 (58) .85
Karnofsky score before transplant >90 442 (73) 393 (71) .22
Disease at transplant .74
AML 160 (26) 131 (24)
ALL 114 (19) 111 (20)
CML 237 (39) 224 (41)
MDS 95 (16) 85 (15)
Disease status at transplant .62
Early 285 (47) 244 (44)
Intermediate 137 (23) 142 (26)
Advanced 154 (25) 136 (25)
Other MDS 30 (5) 29 (5)
Graft type .44
Bone marrow 551 (91) 508 (92)
Peripheral blood 55 (9) 43 (8)
Conditioning regimen .75
Cy/TBI  other 464 (77) 415 (75)
TBI  other 25 (4) 20 (4)
Bu/Cy  other 98 (16) 103 (19)
Bu þ melphalan  other 12 (2) 8 (1)
Other 7 (1) 5 (1)
GVHD prophylaxis .80
Cyclosporine þ MTX  other 354 (58) 334 (61)
Cyclosporine  other (no MTX) 18 (3) 21 (4)
Tacrolimus  other 124 (20) 107 (19)
MTX  other (no cyclosporine) 7 (1) 5 (1)
Ex vivo T cell depletion 100 (17) 83 (15)
Other 3 (<1) 1 (<1)
Donorerecipient sex match .98
Maleemale 244 (40) 223 (40)
Maleefemale 142 (23) 128 (23)
Femaleemale 108 (18) 94 (17)
Femaleefemale 112 (18) 106 (19)
Donorerecipient CMV match .91
Negativeenegative 215 (35) 205 (37)
Negativeepositive 166 (27) 151 (27)
Positiveenegative 105 (17) 93 (17)
Positiveepositive 103 (17) 84 (15)
Unknown 17 (3) 18 (3)
Median donor age, yr (range) 37 (18-60) 35 (18-60) .20
Donor age, yr .55
18-19 6 (1) 4 (1)
20-29 150 (25) 150 (27)
30-39 226 (37) 215 (39)
40-49 183 (30) 143 (26)
50 and older 41 (7) 39 (7)
Year of transplant .15
1990 11 (2) 17 (3)
1991 16 (3) 21 (4)
1992 35 (6) 21 (4)
1993 30 (5) 26 (5)
1994 56 (9) 37 (7)
1995 47 (8) 37 (7)
1996 43 (7) 36 (7)
1997 48 (8) 46 (8)
(Continued)
Table 1
(continued)
Characteristic TT þ CT CC P
1998 70 (12) 54 (10)
1999 46 (8) 69 (13)
2000 87 (14) 83 (15)
2001 83 (14) 69 (13)
2002 34 (6) 35 (6)
Median follow-up of survivors, mo
(range)
95 (3-194) 96 (22-196) .12y
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; MDS, myelodysplastic syndromes; Cy,
cyclophosphamide; TBI, total body irradiation; BU, busulfan; MTX, metho-
trexate; CMV, cytomegalovirus.
Values are total number of cases with percents in parentheses, unless
otherwise noted.
* Data were Corrective action plan (CAP) -modeled.
y Log-rank P value.
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performed a subset analysis of bone marrow graft type
comparing OS, DFS, and TRM outcomes in the validation
cohort. There was no association, whether the model wasTable 2
Discovery and Validation Cohort Multivariate Analysis of Donor rs10912564
Genotypes TT þ CT versus CC
Outcome rs10912564
Genotype
n Hazard
Ratio
95% Conﬁdence
Interval
P
OS
Discovery TT þ CT 606
CC 551 .823 (.718-.953) .0085
Validation TT þ CT 614
CC 571 1.036 (.893-1.202) .6405
DFS
Discovery TT þ CT 606
CC 551 .855 (.743-.984) .0291
Validation TT þ CT 604
CC 561 1.059 (.915-1.226) .4408
TRM
Discovery TT þ CT 606
CC 551 .778 (.65-.931) .006
Validation TT þ CT 606
CC 561 1.013 (.823-1.247) .9039
Relapse
Discovery TT þ CT 606
CC 551 .979 (.777-1.233) .857
Validation TT þ CT 604
CC 561 1.083 (.883-1.329) .4448
aGVHD grades
II-IV
Discovery TT þ CT 606
CC 551 .903 (.769-1.06) .2117
Validation TT þ CT 614
CC 572 .995 (.841-1.177) .951
aGVHD grades
III-IV
Discovery TT þ CT 606
CC 551 1.062 (.838-1.346) .618
Validation TT þ CT 606
CC 564 .948 (.731-1.230) .6888
cGVHD
Discovery TT þ CT 606
CC 551 .931 (.777-1.114) .4339
Validation TT þ CT 600
CC 557 .986 (.838-1.160) .8648
Comparison for all categories is (TT þ CT) vs. CC. Covariates used included
disease, disease status, conditioning regimen, CMV match, Karnofsky score,
graft type, GVHD prophylaxis, year of transplant, recipient age, donor age,
and sex.
Figure 1. Donor TNFSF4 rs10912564 C/C genotype versus C/T and T/T in a discovery cohort. Kaplan-Meier curves for (A) DFS, (B) patient OS, (C) cumulative incidence
of TRM, and (D) cumulative incidence of relapse in the 10 years after transplantation. (E) Cumulative incidence curves for aGVHD grades II to IV (E) and III to IV (F) in
the ﬁrst 100 days after transplantation.
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(all P > .44) or validation (all P > .46) cohorts.
Analysis of Linkage of Genetic Variants in TNFSF4
In the TNFSF4 gene encoded on chromosome 1, we iden-
tiﬁed rs10912564C/T as a potential SNP marker based on its
minor genotypic frequency TT > .05 within the white pop-
ulation and ability to tag in linkage 5 other SNPs (rs7525284,
rs4081545, rs3861950, rs11811856, and rs7514229) each
located in the ﬁrst intron of TNFSF4, except rs7514229, which
is in the 30 untranslated region (Figure 2). Because of the
strong linkage disequilibrium, the haplotype created by the
6 SNPs had a minor allelic frequency (29.4%) in whites fromthe CEU Hapmap population that was similar to the fre-
quency of the rs10912564 T allele (31.8%) in our patient
population. Each tagged TNFSF4 SNP was scored for func-
tional relevance using the F-SNP bioinformatics algorithm
which cross-references 16 bioinformatics tools and data-
bases to generate a SNP score on a 0 to 1 scale where high
scoring SNPs are known to be disease associated [33,34]. The
algorithm used TFSearch version 1 [3] to score potential
transcription factor binding sites in the C and T rs10912564
SNP variant sequence with a threshold of 85. A score of
90.9 was observed between the C variant and myeloblastosis
viral oncogene homolog (v-myb), which was not present in
the T variant. The F-SNP readout indicated v-myb was the
Table 3
Characteristics of Patients Receiving Myeloablative Transplants for AML,
ALL, CML, or MDS Reported to the NMDP for the Discovery and Validation
Cohorts
Variable Discovery
Cohort
Validation
Cohort
P
Number of patients 1301 1200
Number of centers 119 125
Median age, yr (range) 36 (<1-65) 38 (<1-70) .003
Age at transplant, yr <.0001
<1-9 99 (8) 90 (8)
10-19 133 (10) 152 (13)
20-29 206 (16) 212 (18)
30-39 337 (26) 186 (16)
40-49 344 (26) 263 (22)
50 and older 182 (14) 297 (25)
Recipient race
White N/A 1059 (90)
African American N/A 31 (3)
Asian/Paciﬁc Islander N/A 12 (1)
Hispanic N/A 66 (5)
Native American N/A 3 (<1)
Other/missing/unknown/TBD N/A 29
Male sex 747 (57) 673 (56) .5
Karnofsky score before
transplant
.51
<90 321 (25) 280 (23)
90 936 (72) 767 (64)
Missing/unknown 44 153
Disease <.0001
AML 326 (25) 571 (48)
ALL 251 (19) 350 (29)
CML 526 (40) 175 (15)
MDS 198 (15) 104 (9)
Disease stage
Early 589 (45) 500 (42)
Intermediate 325 (25) 377 (31)
Advanced/Late 323 (25) 323 (27)
Other 64 (5) 0
Graft Type <.0001
Marrow 1195 (92) 490 (41)
PBSC 106 (8) 710 (59)
Donor SNP rs10912564 .88
TT 111 (10) 119 (10)
CT 495 (43) 497 (42)
CC 551 (48) 572 (48)
Missing/Unknown 144 12
Donorerecipient sex match .53
Maleemale 527 (41) 475 (40)
Maleefemale 309 (24) 315 (26)
Femaleemale 220 (17) 198 (17)
Femaleefemale 245 (19) 212 (18)
Donorerecipient CMV match <.0001
Donor/recipient 477 (37) 387 (32)
Donor/recipientþ 357 (27) 440 (37)
Donorþ/recipient 215 (17) 140 (12)
Donorþ/recipientþ 215 (17) 213 (18)
Unknown 37 (3) 20 (2)
GVHD prophylaxis <.0001
FK506 þ (MTX or MMF or
steroids)  other
281 (22) 681 (57)
FK506  other 3 (<1) 72 (6)
CSA þ MTX  other 760 (58) 288 (24)
CSA  other 38 (3) 53 (4)
MTX  other 4 (<1) 0
Ex vivo T cell depletion 212 (16) 83 (7)
Other 3 (<1) 23 (2)
Median donor age, yr (range) 36 (18-60) 33 (18-60) <.0001
Donor age in decades <.0001
18-19 12 (1) 18 (2)
20-29 336 (26) 410 (34)
(Continued)
Table 3
(continued)
Variable Discovery
Cohort
Validation
Cohort
P
30-39 505 (39) 449 (37)
40-49 354 (27) 265 (22)
50 and older 94 (7) 58 (5)
Donor race
White N/A 1033 (89)
African American N/A 30 (3)
Asian/Paciﬁc Islander N/A 11 (1)
Hispanic N/A 17 (1)
Native American N/A 13 (1)
Other/declined/unknown N/A 62 (5)
Missing/TBD N/A 34
Year of transplant <.0001
1990 30 (2) 0
1991 46 (4) 0
1992 58 (4) 0
1993 61 (5) 0
1994 105 (8) 0
1995 98 (8) 0
1996 86 (7) 0
1997 118 (9) 0
1998 144 (11) 0
1999 137 (11) 0
2000 181 (14) 0
2001 161 (12) 0
2002 76 (6) 0
2003 0 165 (14)
2004 0 248 (21)
2005 0 324 (27)
2006 0 354 (30)
2007 0 109 (9)
Median follow-up of survivors,
mo (range)
96 (3-196) 71 (11-109) <.0001*
N/A indicates not available; TBD, to be determined; PBSC, peripheral blood
stem cell; FK506, tacrolimus; MMF, mycophenolate mofetil; CSA, cyclo-
sporine.
Values are number of cases with percents in parentheses, unless otherwise
noted.
* Log-rank P value.
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rs10912564 variants. F-SNP analysis of the SNPs tagged with
rs10912564 showed rs4081545 as a potential binding site for
nuclear factor-1 and rs7514229 as a site for caudal type
homeobox 1 (Cdx-1) with scores above threshold (Figure 2).
Functional Relevance of TNFSF4 SNP rs10912564
To determine whether rs10912564 had any effect on the
function of TNFSF4, we initially used the SNP bioinformatics
database F-SNP to search for potential functional changes in
protein coding, splicing regulation, transcriptional regula-
tion, transcription regulation, or post-translation involving
SNP rs10912564. We found rs10912564 was located within a
potential Myb binding site. To further explore the possibility
that the rs10912564 T/C variant could augment the binding
of transcription factor c-myb, we created a DNA protein
interaction ELISA assay to assess the ability of c-myb to bind a
biotinylated 30mer sequence of TNFSF4 containing either the
T or C rs10912564 variant. We used Jurkat cells shown to
express c-myb in nuclear extracts as our source of c-myb
protein [35]. Upon comparison, we found c-myb bound
signiﬁcantly stronger to the C biotinylated probe compared
with the T variant (Figure 3A, P ¼ .0024). To check the
speciﬁcity of the assay we performed a competition experi-
ment. As shown in Figure 3B, adding excess amount of
Figure 2. TNFSF4 gene organization as depicted in the NCBI database and analysis of SNPs in linkage with rs10912564. The TNFSF4 gene is on chromosome 1q25 and
is a 3-exon, 2-intron gene. Filled boxes denote exons, unﬁlled boxes indicate untranslated regions, and solid lines between boxes represent introns in the TNFSF4 gene
diagram. The relative positions of the TNFSF4 variants tagged with rs10912564 are indicated along with their percent of linkage disequilibrium calculated in Hap-
loview. A haplotype frequency is noted for the linked major alleles compared with minor alleles. The assessment of each SNPs functional relevance was calculated
using F-SNP bioinfomatics algorithm. Potential transcription factor binding sites altered by the SNP polymorphism are listed.
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to the plate bound rs10912564C probe. To functionally
determine if these variants effect cellular responses, we
collected peripheral blood mononuclear cells from 4 donors
of each rs10912564 genotype and stimulated themwith IgM
and anti-CD40 antibodies for 72 hours and assessed their
ability to upregulate TNFSF4 on B cells. Stimulation led to an
increase in the percentage of TNFSF4þCD19þ B cells in donors
carrying the CC genotype compared with CT and TT, sug-
gesting the rs10912564C allele may augment the expression
level of TNFSF4 (Figure 4, P ¼ .049). These data highlight the
potential functional capacity of SNP rs10912564 to regulate
transcription factor binding to TNFSF4 and the expression
level on the cell surface of B cells.
DISCUSSION
Efforts to identify risk factors such as HLA mismatch
have had a signiﬁcant impact on improving the outcomes of
HSCT [36,37]. These studies allowed for better matching of
recipients and donors. However, the rate of post-HSCT
complications remains high. A main focus has been to
investigate the importance of genetic polymorphisms in
immunoregulatory genes in determining HSCT outcomes
post-transplant [5,38-40]. Virtually all post-HSCT complica-
tions are immune response driven; therefore, we focused on
the role of costimulatory molecules by examining the asso-
ciation between 9 SNPs in 5 costimulatory genes and HSCT
outcomes in unrelated HLA-matched donorerecipient pairs.These costimulatory molecules play a key role in deter-
mining the outcome of immune responses [41-43]. Our
dataset of 2570 donorerecipient pairs collected from 2 in-
dependent cohorts represents 1 of the largest SNP studies
assembled focused on TNFSF4, which is expressed on B cells,
vascular endothelial cells, natural killer cells, and mast cells
and provides clonal expansion of antigen-speciﬁc T cells,
expansion of regulatory T cells, and generation of T cell
memory [15,44].
The TNFSF4 rs10912564CC genotype of donors was asso-
ciated with a higher likelihood of OS with less TRM in our
discovery cohort. This association between rs10912564CC
and less TRM may reﬂect the costimulatory capacity of the
reconstituted immune system by the donor leukocytes [9]. In
support of our discovery ﬁndings, it was demonstrated in a
cohort of patients that low responders to hepatitis B vacci-
nation were more likely to have the rs10912564 T allele [45].
The effect of TNFSF4 on infection clearance has been heavily
supported in a number of studies. For instance, prolonged
immunity has been observed against mycobacterium tuber-
culosis when vaccination is delivered in conjunction with a
TNFSF4:Ig fusion protein, generating a strong Th1 cytokine
response [16,46,47]. Furthermore, T cells lacking TNFRSF4 fail
to accumulate in response to a chronic viral infection that is
associated with decreased survival proteins Bcl-2 and Bcl-xL
[32]. In future studies a correlation between infection rate
with genetic variants in marrow grafts could identify in-
dividuals at higher risk for infection after HSCT and would
Figure 3. Speciﬁc binding of c-myb to a 30-oligomer sequence of TNFSF4
containing the rs10912564 polymorphism. (A) Binding of c-myb to a 30-mer
oligonucleotide probe containing either the rs10912564 C or T variant in the
center. Binding was measured as a function of absorbance at 450 nm after a
peroxidase reaction. Data represent 3 independent experiments. (B) The
speciﬁc binding of c-myb to the rs10912564C probe was shown by a compe-
tition experiment with nonbiotinylated dsDNA. Different concentrations of
probe (100, 1000 pmol) were added to Jurkat nuclear extract and incubated
on an ELISA plate coated with 2 pmol of biotinylated rs10912564C probe
and absorbance read at 450 nm after a peroxidase reaction. Data represent
2 independent experiments. B indicates blank; Bio, biotinylated; c-myb,
myeloblastosis viral oncogene homolog.
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toring and treating this subset of patients to optimize clinical
outcomes.
Because we evaluated a clinical association between
rs10912564 genotypes and HSCT outcomes, we strived to
develop a possible mechanism of action. Functional SNPs are
known to mainly interact in gene promoter regions; how-
ever, noncoding intronic sequences may contain functional
SNPs that can enhance the transcriptional level of genes
leading to disease associations [48,49]. Regulatory elements
located in the ﬁrst intron have been identiﬁed as sites
of transcriptional regulation [50]. Examination of SNP
rs10912564 using bioinformatics tools helped us to pinpoint
the c-myb binding site consensus sequence as a possible
functionally relevant site inwhich the C nucleotide would be
predicted to be a critical base required for c-myb binding
[51]. We speculate that rs10912564C creates a stable binding
site for c-myb that could potentially augment the expression
of TNFSF4 in comparison with the T allele. Many genes are
upregulated through the binding of c-myb, which is induced
after activation of T and B cells and is required for the dif-
ferentiation and survival of the B cell lineage [52-54]. The
location of the rs10912564 polymorphism in the intron1 region suggests it affects the creation of a transactivator
enhancer or interacts with regulatory elements required for
gene expression.
This study has strengths and limitations. First, this
study represents 1 of the largest non-HLA genetic association
studies using a well-deﬁned discovery cohort of 1157
donorerecipient pairs. We meticulously chose SNPs in
candidate immunoregulatory genes, which were known to
have pivotal roles in various outcomes post-transplantation.
The main limitation in this study was the inability to repli-
cate our association data in a more recent validation cohort
where the signiﬁcance of TNFSF4 SNP rs10912564 was
negligible, suggesting the absence of a true association or
indicative of a small size effect. The latter is an important
aspect of gene association studies for complex diseases,
because most individual disease-associated SNPs exhibit
modest effects on relative risk. A typed SNP may serve as an
imperfect surrogate for the true causal SNP, suggesting a joint
effect of multiple SNPs. Multiple comparisons in clinical
outcome-driven SNP studies might require a more stringent
P value; however, our TRM P value (.006) met rigidity
required to adjust for multiple comparisons. Furthermore,
we tried to reduce the burden of multiple comparisons by
having high statistical power with prior literature supported
knowledge of the effect these candidate genes had on HSCT
outcomes. If the ever-evolving ﬁeld of clinical bone marrow
transplantation obscured the effect of our SNP, it sheds light
on a challenge for genetic association studies in this ﬁeld and
virtually for all other ﬁelds that therapies and standard of
practice change over time. Furthermore, the actual contri-
bution of a SNP to the biology of a gene and novel insights
drawn from the data, even obscured, facilitates better un-
derstanding of the mechanisms by which the gene might
affect disease.
The lack of validation could also be due to the signiﬁcant
differences between the discovery and validation cohorts.
The validation cohort included an increased number of older
patients than the discovery cohort, and this older patient
population was associated with more acute leukemias.
Furthermore, the newer validation cohort had access to a
much younger donor population, highlighting improvement
in donor options via registry growth in recent years. Addi-
tionally, the validation group beneﬁted from recent changes
in HSCT technique in that graft types have transitioned to
peripheral blood stem cell transplants. Finally, the validation
cohort used more FK506/tacrolimus for GVHD prophylaxis,
which has been associated with less aGVHD and better out-
comes compared with the cyclosporine Aebased treatments
used in the discovery cohort [55]. Moreover, ex vivo T cell
depletion was used in the discovery cohort and is associated
with poor engraftment and higher relapse rates [56].
Conversely, the validation cohort had little to no ex vivo T cell
depletion. Although we made an effort to incorporate the
differences between the discovery and validation cohorts in
our analysis, we cannot completely rule out that they did not
signiﬁcantly impact the effect of SNP rs10912564 on HSCT
outcomes.
In conclusion, although we found associations between
TNFSF SNP rs10912564 and HSCT outcomes in our discovery
cohort and were able to show the functional contribution of
the SNP, our ﬁndings were not validated in a more recent
cohort. We believe a larger prospective study is warranted to
examine the inﬂuence of TNFSF4 genetic variants on post-
transplant outcomes as well as indepth functional studies
on speciﬁc subsets of immune cells to determine the
Figure 4. TNFSF4 surface expression on CD19þ B cells from HSCT donor peripheral blood mononuclear cells. Peripheral blood mononuclear cells (n ¼ 12) from each
TNFSF4 rs10912564 genotype (n ¼ 4) were stimulated with 10 mg/mL IgM and 5 mg/mL anti-CD40 antibodies for 72 hours. (A) Overlaid histograms were normalized
and depicted as the % of max for the CC (i), TC (ii), and TT (iii) genotypes. Black histograms indicate TNFSF4 staining of stimulated B cells, and the gray histograms
indicate TNFSF4 staining of unstimulated B cells. A negative baseline cutoff was created based on isotype staining demarcated where the negative and positive
histogram markers overlap. (B) The percentage of TNFSF4 positive B cells was calculated in the presence and absence of stimulation. The average difference in the
percentage of TNFSF4 positive B cells with and without stimulation for each genotype was plotted with standard error of mean.
P.T. Jindra et al. / Biol Blood Marrow Transplant 22 (2016) 27e36 35potential impact of TNFSF4 genetic variants regulating their
function.
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